Drug maker Celltrion seeks revocation of Novartis’ asthma treatment patent in UK trial
Celltrion, a South Korean pharmaceutical company, asked the UK High Court to invalidate an asthma treatment patent jointly owned by drugmakers Greentech and Novartis. In opening arguments today, Celltrion claimed it...To view the full article, register now.
Already a subscriber? Click here to view full article